Ania Jastreboff
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1780788349
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Eli Lilly at 30.7% of the total. 2025 is the largest year on record at $146,537, 2.9 times the $50,997 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $1035.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$165K
- Novo Nordisk AS$123K
- Novo Nordisk$86K
- Amgen$45K
- Boehringer Ingelheim$27K
- Boehringer Ingelheim International GmbH$20K
- plus $70K from 15 others
Across 885 payments — averaging $1965.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1M
- Novo Nordisk AS$317K
- Boehringer Ingelheim$173K
- Amgen$91K
- Rhythm Pharmaceuticals, Inc.$85K
- Boehringer Ingelheim International GmbH$24K
What the payments were for
- Consulting fees$317,21659%
- Speaking & faculty fees$24,7335%
- Travel & lodging$179,46234%
- Food & beverage$14,1173%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 255 | $164,546 |
| Novo Nordisk AS | 51 | $122,764 |
| Novo Nordisk | 77 | $86,241 |
| Amgen | 16 | $44,980 |
| Boehringer Ingelheim | 27 | $27,113 |
| Boehringer Ingelheim International GmbH | 35 | $19,827 |
| Lilly USA, LLC | 11 | $15,689 |
| Zealand Pharma A/s | 6 | $14,048 |
| Regeneron | 11 | $10,973 |
| Pfizer | 4 | $7,300 |
| F. Hoffmann-la Roche AG | 4 | $6,254 |
| Astrazeneca UK Limited | 4 | $4,115 |
| AstraZeneca | 5 | $4,028 |
| Rhythm Pharmaceuticals, Inc. | 2 | $3,668 |
| Astrazeneca AB | 3 | $2,160 |
| Novo Nordisk Health Care AG | 1 | $1,360 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Medtronic | 1 | $94 |
| Covidien LP | 1 | $81 |
| Corcept Therapeutics | 1 | $50 |
| Johnson & Johnson | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$535,527 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 33 | $33,954 |
| OzempicSemaglutide | 22 | $20,547 |
| Metformin Hcl ErMetformin Hcl | 26 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $15,689 | $33,95433 claims |
| Novo NordiskOzempic | $86,241 | $20,54722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in New Haven
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Gerald ShulmanNew Haven$194K
- Karl InsognaNew Haven$68K
- Clemens BergwitzNew Haven$31K
- Richard KibbeyNew Haven$18K
- Peter TebbenNew Haven$17K
- Surani FernandoNew Haven$13K
- Irina RosewaterNew Haven$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.